Erlotinib mesylate

Research use only, not for human use.

Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM.

Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM; inhibits the proliferation of DiFi human colon tumor cells at submicromolar concentrations in cell culture and blocks cell cycle progression at the G1 phase; 100mg/kg completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice; orally active.Lung Cancer Approved

CP-358774;OSI-774;NSC 718781;R 1415

Angiogenesis

EGFR

EGFR

Cancer

Lung Cancer

248594-19-6

489.54

C23H27N3O7S

>98% (HPLC)

10 mM in DMSO

COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.CS(=O)(=O)O

4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years